Related Experiment Video
Updated: Aug 16, 2026
Large-Scale Preparation of Synovial Fluid Mesenchymal Stem Cell-Derived Exosomes by 3D Bioreactor Culture
Published on: July 26, 2022
Secretome Derived from Umbilical Cord Mesenchymal Stem Cells as a Therapeutic Approach for Osteoarthritis: Insights
Wahyu Widowati1,2, Lydia Lydia3, Gabriella Rumayauw J3
1Master Program of Skin Aging and Aesthetic Medicine, Faculty of Medicine, Maranatha Christian University, Bandung, West Java, 40164, Indonesia. wahyu_w60@yahoo.com.
Abstract:
Osteoarthritis (OA) is a chronic degenerative joint disorder characterized by articular cartilage deterioration, synovial inflammation, and progressive loss of joint function. Current treatments predominantly address symptoms without modifying structural disease progression, highlighting the need for disease-modifying strategies. Mesenchymal stem cells (MSCs), particularly umbilical cord-derived MSCs (UC-MSCs), exert therapeutic effects primarily through paracrine mechanisms rather than direct engraftment. The UC-MSCs secretome, comprising soluble bioactive factors and extracellular vesicles, modulates pro-inflammatory signaling, inhibits chondrocyte apoptosis, and promotes cartilage matrix biosynthesis. In vitro studies demonstrate restoration of anabolic chondrocyte phenotype, suppression of catabolic enzymes (MMP-13, ADAMTS-5), and attenuation of NF-κB and MAPK pathway activation. Preclinical models show preservation of cartilage architecture, reduced synovial inflammation, and improved joint function following intra-articular administration. Early clinical investigations report reductions in pain scores and functional improvements with favorable short-term safety profiles, though evidence remains largely derived from MSCs-based rather than secretome-specific interventions. Current findings support the biological plausibility and translational potential of UC-MSCs secretome therapy; however, clinical evidence remains limited and heterogeneous. Adequately powered randomized controlled trials with standardized protocols and extended follow-up are required to establish long-term efficacy and safety.
Insights
Mesenchymal stem cell secretome therapy shows promise for osteoarthritis by reducing inflammation and promoting cartilage repair. Further clinical trials are needed to confirm long-term effectiveness and safety for this disease-modifying approach.
Area of Science:
- Regenerative Medicine
- Orthopedics
- Cell Biology
Background:
- Osteoarthritis (OA) is a degenerative joint disease with limited disease-modifying treatments.
- Current OA therapies primarily manage symptoms, not disease progression.
- Mesenchymal stem cells (MSCs), especially from umbilical cords (UC-MSCs), offer potential therapeutic benefits via paracrine signaling.
Purpose of the Study:
- To evaluate the therapeutic potential of UC-MSC secretome for osteoarthritis.
- To investigate the mechanisms underlying UC-MSC secretome's effects on cartilage and inflammation.
- To assess the clinical translation and evidence for UC-MSC secretome therapy in OA.
Main Methods:
- In vitro studies analyzing chondrocyte phenotype, apoptosis, and inflammatory pathways (NF-κB, MAPK).
- Preclinical models assessing cartilage preservation, inflammation, and joint function after intra-articular UC-MSC secretome administration.
- Review of early clinical investigations on UC-MSC secretome therapy for OA.
Main Results:
- UC-MSC secretome promotes anabolic chondrocyte function and cartilage matrix synthesis in vitro.
- It inhibits catabolic enzymes (MMP-13, ADAMTS-5) and inflammatory signaling pathways.
- Preclinical studies demonstrate cartilage protection, reduced inflammation, and improved joint function.
- Early clinical trials show pain reduction and functional improvement with good short-term safety.
Conclusions:
- UC-MSC secretome therapy exhibits biological plausibility and translational potential for osteoarthritis.
- Therapeutic effects are mediated by soluble factors and extracellular vesicles, not cell engraftment.
- Limited and heterogeneous clinical evidence necessitates large-scale, standardized randomized controlled trials for definitive efficacy and safety assessment.
More Related Videos
Related Concept Videos
01:19Mesenchymal Stem Cells
01:21Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...